Get the app
US › Healthcare

Dogwood Therapeutics, Inc. (DWTX)

US · Healthcare · Biotechnology

$1.22-2.40%
Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue
$0
Net profit
$-11.5M
EPS
$-0.34
EPS estimate
$-0.13

EPS came in at -0.34 against a street estimate of -0.13 — a miss of 161.5%.

Key statistics

Market cap
$42.5M
P/E
0.6
Forward P/E
0.0
P/B
0.75
Book value
$2.03
EPS (TTM)
$2.20
52-week high
$7.04
52-week low
$1.18
50-day MA
$1.87
200-day MA
$2.12
Beta
1.94

Analyst view

Analysts rate Dogwood Therapeutics, Inc. a strong buy (2 buy, 0 hold, 0 sell out of 2) with an average price target of $14.00.

Shareholding

Insiders
72.57%
Institutions
11.47%

Largest institutional holders

FundStake
Armistice Capital, LLC9.22%
Millennium Management LLC1.01%
Vanguard Capital Management, LLC0.39%
Geode Capital Management, LLC0.26%
Vanguard Fiduciary Trust Co0.18%
BlackRock Inc0.08%
Northern Trust Corp0.07%
Citadel Advisors Llc0.03%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Dogwood Therapeutics, Inc. — free to start.

Open in the appGoogle PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncAmgen IncGilead Sciences IncAbbott LaboratoriesNovo Nordisk A/S

Data updated 2026-10-19.